690 related articles for article (PubMed ID: 21459216)
61. Correspondence.
Lorenzo-Carrero J
Retina; 2009 Jun; 29(6):868-9; author reply 869. PubMed ID: 19516126
[No Abstract] [Full Text] [Related]
62. Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.
Parrish RK; Traverso CE; Green K; Danis RP;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):418-25. PubMed ID: 27183545
[TBL] [Abstract][Full Text] [Related]
63. Fluocinolone Acetonide Intravitreal Implant in the Visual Axis.
Moisseiev E; Morse LS
JAMA Ophthalmol; 2016 Sep; 134(9):1067-8. PubMed ID: 27367921
[No Abstract] [Full Text] [Related]
64. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
65. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
66. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
67. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema.
Dutra Medeiros M; Postorino M; Navarro R; Garcia-Arumí J; Mateo C; Corcóstegui B
Ophthalmologica; 2014; 231(3):141-6. PubMed ID: 24356099
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema.
Guigou S; Pommier S; Meyer F; Hajjar C; Merite PY; Parrat E; Rouhette H; Rebollo O; Matonti F
Ophthalmologica; 2015; 233(3-4):169-75. PubMed ID: 25924737
[TBL] [Abstract][Full Text] [Related]
69. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
[TBL] [Abstract][Full Text] [Related]
70. Dexamethasone intravitreal implant during phacoemulsification.
Agarwal A; Gupta V; Ram J; Gupta A
Ophthalmology; 2013 Jan; 120(1):211, 211.e1-5. PubMed ID: 23283186
[No Abstract] [Full Text] [Related]
71. CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Chakravarthy U; Yang Y; Lotery A; Ghanchi F; Bailey C; Holz FG; Downey L; Weber M; Eter N; Dugel PU
Retina; 2018 Feb; 38(2):343-351. PubMed ID: 28257378
[TBL] [Abstract][Full Text] [Related]
72. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
[TBL] [Abstract][Full Text] [Related]
73. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.
Nguyen QD; Shah SM; Khwaja AA; Channa R; Hatef E; Do DV; Boyer D; Heier JS; Abraham P; Thach AB; Lit ES; Foster BS; Kruger E; Dugel P; Chang T; Das A; Ciulla TA; Pollack JS; Lim JI; Eliott D; Campochiaro PA;
Ophthalmology; 2010 Nov; 117(11):2146-51. PubMed ID: 20855114
[TBL] [Abstract][Full Text] [Related]
74. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
[TBL] [Abstract][Full Text] [Related]
75. Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant.
Galor A; Margolis R; Kaiser PK; Lowder CY
Arch Ophthalmol; 2007 Jun; 125(6):836-8. PubMed ID: 17562999
[No Abstract] [Full Text] [Related]
76. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
77. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
78. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
79. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y
BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265
[TBL] [Abstract][Full Text] [Related]
80. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
Campochiaro PA; Nguyen QD; Hafiz G; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane FE;
Ophthalmology; 2013 Mar; 120(3):583-587. PubMed ID: 23218184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
